Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
12 feb 2008 - 08:02
Statutaire naam
Crucell N.V.
Titel
Crucell Announces Fourth Quarter and Full Year 2007 Results
Bericht
Total revenue and other operating income grew by more than 50% to
€213.1 million, compared to €140.9 million in 2006.
Successful Quinvaxem™ launch drives strong autonomous growth.
Strong operating cash flow of €51.5 million in the fourth quarter and €22.2 million for the year compared to a negative €54.0 million in 2006.
2008 full year guidance: total revenue and other operating income growth of 20% in constant currencies ; higher margins; positive cash flow.
Leiden, The Netherlands (February 12, 2008) – Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced its financial results for the fourth quarter and full year 2007, based on International Financial Reporting Standards (IFRS). These financial results are unaudited.
Datum laatste update: 29 december 2025